• Gudmundur Johannsson, Alberto Falorni, Stanko Skrtic, Hans Lennernäs, Marcus Quinkler, John P Monson, and Paul M Stewart.
• Department of Endocrinology, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
• Clin. Endocrinol. (Oxf). 2015 Jan 1;82(1):2-11.

AbstractGlucocorticoid replacement therapy in patients with adrenal insufficiency (AI), whether primary (Addison's disease) or secondary (due to hypopituitarism), has been established for some 50 years. The current standard treatment regimen involves twice- or thrice-daily dosing with a glucocorticoid, most commonly oral hydrocortisone. Based on previous small-scale studies and clinical perception, life expectancy with conventional glucocorticoid replacement therapy has been considered normal, with a low incidence of adverse events. Data from the past 10-15 years, however, have shown that morbidity remains high and life expectancy is reduced. The increased morbidity and decreased life expectancy appear to be due to both increased exposure to cortisol and insufficient cortisol coverage during infections and other stress-related events. This is thought to reflect a failure of treatment to replicate the natural circadian rhythm of cortisol release, together with a failure to identify and deliver individualized cortisol exposure and to manage patients adequately when increased doses are required. The resulting over- or under-treatment may result in Cushing-like symptoms or adrenal crisis, respectively. This review summarizes the morbidity and mortality seen in patients receiving the current standard of care for AI and suggests areas for improvement in glucocorticoid replacement therapy.© 2014 John Wiley & Sons Ltd.

10 keywords...

hide…